Traders Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of some unusual options trading on Friday. Stock investors purchased 99,010 call options on the stock. This represents an increase of 183% compared to the typical daily volume of 34,985 call options.

Teva Pharmaceutical Industries Trading Up 3.0%

Shares of NYSE:TEVA traded up $0.51 during midday trading on Friday, hitting $17.76. 11,572,328 shares of the stock traded hands, compared to its average volume of 10,140,738. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The business's 50 day moving average is $15.67 and its two-hundred day moving average is $17.38. The stock has a market capitalization of $20.14 billion, a PE ratio of -12.25, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.48 EPS. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president now owns 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.49% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently modified their holdings of the stock. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $44,000. Golden State Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $39,000. New Age Alpha Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $43,000. Finally, Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $66,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Truist Financial started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday. They set a "buy" rating and a $24.00 price objective on the stock. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Nine equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and a consensus target price of $24.44.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.